FORMULATION AND EVALUATION OF ANTIPARKINSON’S DRUG INCORPORATED TRANSDERMAL FILMS
Objective: Ropinirole suitable for transdermal delivery due to its small molecular size (260.37 g/mol), optimum log p (2.3), and low oral bioavailability (50%) due to first-pass metabolism, the short elimination half-life of 4–6 h. Dose of drug is 6 mg/day. Hence, in the present study, an attempt was made to deliver antiparkinson’s drug through transdermal route in the form of transdermal film to attain sustained release using different concentration of drug, polymers stabilizers.
Methods: Among the different formulations of matrix type (F1 to F5), F2 and F4 formulations were optimized based on crystallinity. These formulations were carried out for in vitro permeation studies. Out of these two formulations, F4 formulation showed target drug release.
Results and Discussion: The formulation F4 containing 2 mg drug, 600 mg hydroxypropyl methylcellulose E15 and 50 mg of Eudragit RS 100 was selected as optimized formulation, after considering its microscopic examination throughout stability, % drug content (98.4%), drug permeated through the cellophane membrane at the end of 72 h, and evaluation of physicochemical characterization parameters such as thickness, weight variation, flatness, folding endurance, moisture content, and tensile strength.
Conclusion: The results of physicochemical characterization were ensured the stability of the films. The drug permeation profile was also found to follow Higuchi kinetic model.
2. Eseldin K, Rakesh KS. Transdermal drug delivery system. Design and evaluation. Int J Adv Pharm Sci 2010;1:201-11.
3. Sahu RK. Development and evaluation of transdermal patches of colchicines. Scho Res Lib 2011;4:330-43.
4. Meenakshi B. Devlopment and characterization of transdermal patches of metoprolol tartrate. Asian J Pharm Clin Res 2010;3:130.
5. Gordon RD, Peterson TA. About transdermal drug delivery. Drug Del Tech 2003;3:44-50.
6. Bhosale N. Formulation and evaluation of transdermal patches of ropinirole HCl. Res J Pharm Biol Chem Sci 2011;2:138.
7. Reichmann H. Transdermal delivery of dopamine receptor agonists. Parkinsonism Relat Disord 2009;4:93-6.
8. Vijayan V. Development and physiochemical, in vitro evaluation of antihypertensive transdermal patches. J Pharm Sci Res 2010;2:171-7.
9. Curran MP, Perry CM. Cabergoline: A review of its use in the treatment of parkinson’s disease. Drugs 2004;64:2125-41.
10. Reynolds NA, Wellington K, Easthope SE. Rotigotine: In parkinson’s disease. CNS Drugs 2005;19:973-81.
11. Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P, Vogt-Ferrier N. Use of transdermal drug formulations in the elderly. Drugs Aging 2008;25:269 80.
12. Nashatizadeh MM, Lyons KE, Pahwa R. A review of ropinirole prolonged release in parkinson’s disease. Clin Interv Aging 2009;4:179 86.
13. Chandrashekar NS, Shobha Rani RH. Physicochemical and pharmacokinetic parameters in drug selection and loading for transdermal drug delivery. Indian J Pharm Sci 2008;70:94-6.
14. Bhosale NR, Hardikar SR, Bhosale AV. Formulation and evaluation of transdermal patches of ropinirole. HCl. Res R Pharm Biol Chem Sci 2011;2:138-45.
15. Shivaraj A. Design and evaluation of transdermal drug delivery of ketotifen fumarate internatio. Int J Pharm Biomed Res 2010;1:42-7.
16. Dangi A. Formulation and evaluation of transdermal ondansetron hydrochloride matrix patch: In vitro skin permeation and irritation study. Int J Pharm Res Allied Sci 2012;1:26-34.
17. Sanjay D, Ananya M. Preparation of carvedilol transdermal patch and the effect of propylene glycol on permeation. Int J Pharm Pharm Sci 2010;2:83.
18. Ganju E. Formulation and evaluation of transdermal patch of prochlorperazine maleate for hyperemesis gravidarum. Int J Res Pharm Chem 2011;1:1115-8.
19. Raju RT. Formulation and evaluation of transdermal drug delivery systems for lercanidipine hydrochloride. Int J Cur Pharm Res 2010;2:253-8.
20. Arora P, Mukherjee B. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal patches containing diclofenac diethylammonium salt. J Pharm Sci 2002;91:2076-89.
21. Amnuaikit C, Ikeuchi I, Ogawara K, Higaki K, Kimura T. Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use. Int J Pharm 2005;289:167-78.
22. Kusum Devi V, Saisivam S, Maria GR, Deepti PU. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev Ind Pharm 2003;29:495-503.
23. Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone-ethylcellulose matrices. Drug Dev Ind Pharm 2003;29:1-7.
24. Dipanjana AS, Sutapa BM, Gopa RB. Oleogels of olive oil and soybean oil for topical drug delivery: A comparative analysis. Int J Pharm Pharm 2019;11:4-10.
25. Dina MH, Nermin MS, Vivian SE, Wedad S. Enhancing the sunscreen efficacy of bemotrizinol micropigment by using o/w nanoemulsion topical preparations. Int J Pharm Pharm Sci 2019;11:47-56.
26. Rakesh PP, Grishma P, Ashok B. Formulation and evaluation of transdermal patch of aceclofenac. Int J Drug Del 2009;1:41-51.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.